Evolving Treatment Strategies in Relapsed/Refractory Multiple Myeloma: Integrating Bispecific Antibodies into Earlier Lines of Care

Dr. Binod Dhakal opens the discussion by introducing the evolving treatment landscape in relapsed/refractory multiple myeloma (RRMM), highlighting the growing impact of frontline quadruplet regimens and anti-CD38 therapies on treatment decision-making at relapse. Dr. Carol Ann Huff discusses key considerations for patient identification in the second-line setting, emphasizing the importance of evaluating prior therapies, lenalidomide refractoriness, anti-CD38 exposure versus refractoriness, duration of remission, disease biology, and risk features. She explains that many patients now present with lenalidomide-refractory disease due to maintenance therapy and may also have prior anti-CD38 exposure, requiring a more individualized treatment approach. The conversation also highlights the role of patient preferences and shared decision-making when selecting subsequent therapy. Overall, the segment provides a framework for assessing patients with RRMM at first relapse and tailoring treatment strategies based on both disease- and patient-specific factors.